DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for nervous system disease — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNervous system disease maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside nervous system disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Cryo-EM structure of human KCNQ4 — Ezogabine has a real, experimentally solved structure in complex with this target (PDB 7BYM, 3.1 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet fbxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7BYM · 3.1 Å · ligand Ezogabine (FBX). Experimental structure, not a prediction.
What the evidence adds up to
The 2020 review of drug repurposing in neurological diseases describes the approach as studying clinically approved drugs in one disease to see if they have therapeutic value without triggering side effects in other diseases. It notes that the structural complexity of the nervous system and the influence of blood–brain barrier permeability make drug development in neuropathological conditions more difficult than in other organs, and that repurposing is therefore of particular importance. The chapter summarises repurposing candidates currently in clinical trials for neurological diseases, along with potential mechanisms and preliminary results, but does not report any concrete survival or response rates from those trials. The 2004 neuroepidemiology chapter provides a review of study design for neurological conditions, emphasising the importance of defining the research question, choosing the study population, and defining study outcomes, but contains no drug-specific data. The 2019 basic review lists Alzheimer’s disease, Parkinson’s disease, Guillain-Barré syndrome, and myasthenia gravis as main nervous system diseases, but offers no trial results or repurposing evidence. The 2024 issue information describes a symposium on cholinergic mechanisms and references a preface article, but provides no clinical data on any drug.
No abstract in this set reports a completed repurposing trial with measurable outcomes for any specific nervous system disease. The 2020 review acknowledges that repurposing candidates are in clinical trials and that preliminary results exist, but it does not give numbers for survival, response rates, or sample sizes. The other abstracts are methodological or educational and contain no efficacy data. There is no evidence here that any repurposed drug has improved survival or symptom control in any neurological condition.
What is missing is any published trial with patient-level data. The 2020 review does not specify which repurposing candidates have reached late-stage testing, nor does it provide stratified results by disease subtype or blood–brain barrier status. Without funding for randomised controlled trials that report concrete endpoints, and without patient stratification to account for the heterogeneity of neurological diseases, the promise of repurposing remains untested in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
IntechOpen eBooks · 2020 · 6 citations · open access
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
AbstractDrug repurposing or repositioning refers to “studying of clinically approved drugs in one disease to see if they have therapeutic value and do not trigger side effects in other diseases.” Nowadays, it is a vital drug discovery approach to explore new therapeutic benefits of existing drugs or drug candidates in various human diseases including neurological disorders. This approach overcomes the shortage faced during traditional drug development in grounds of financial support and timeline. It is especially hopeful in some refractory diseases including neurological diseases. The feature that structure complexity of the nervous system and influence of blood–brain barrier permeability often becomes more difficult to develop new drugs in neuropathological conditions than diseases in other organs; therefore, drug repurposing is particularly of utmost importance. In this chapter, we discuss the role of drug repurposing in neurological diseases and make a summarization of repurposing candidates currently in clinical trials for neurological diseases and potential mechanisms as well as preliminary results. Subsequently we also outline drug repurposing approaches and limitations and challenges in the future investigations.
AbstractAbstract This chapter provides a review of essential concepts, including an overview of the nervous system and methods for diagnosing neurologic disease. Knowledge of the unique characteristics of the nervous system is essential to the design and conduct of studies of neurologic diseases. The chapter provides an overview of epidemiologic study design, emphasizing aspects that are particularly important in the investigation of neurologic disease. These sections emphasize the importance of defining the research question, choosing the study population, and defining study outcomes. A particular focus is the unique methodological considerations for studying neurological conditions.
International Journal of Neurology Research · 2019 · 0 citations · open access
Diseases of the nervous system: A basic review
AbstractNervous System (basic review) are to understand very easily for graduate, post graduate and post doctoral ayush, dental, medical etc., students. I am explaining main and important diseases in nervous system in day to day practical life for medical students and professionals. Diseases are Alzheimer’s disease, Parkinson’s disease, Gillian Barr’s syndrome and myasthenia gravis.
Journal of Neurochemistry · 2024 · 0 citations · open access
Issue Information
AbstractFront cover This special issue related to the 17th Symposium on Cholinergic Mechanisms (ISCM2022) highlights the progress in the molecular, neurochemical, pharmacological, toxicological, and clinical studies of the cholinergic system, underlining its complexity and impact on health and disease. The most recent ISCM2022 was organized in a hybrid format, allowing flexibility due to travel restrictions caused by the COVID pandemics. Image content The figure highlights the conference logo, with acetylcholine in Dubrovnik's common ornament carved in stone. Designed by Grafokor, Croatia. Read the full article ‘Recent advances in cholinergic mechanisms: A preface for the ISCM2022 special issue’ by Z. Kovarik and H. Soreq (J. Neurochem. vol. 168 (4), pp. 334–338) on doi: 10.1111/jnc.16027
AJN American Journal of Nursing · 2011 · 0 citations
New Drug Treats Partial Seizures
AbstractEzogabine (Potiga), the first neuronal potassium channel opener, has been approved for the treatment of partial seizures in adults. Precautions are necessary because it can produce urinary retention, QT interval prolongation, or increased suicidal ideation or behaviors. Ezogabine can also produce a variety of adverse central nervous system effects.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
